Northwestern Mutual Wealth Management Co. Reduces Holdings in Cue Biopharma, Inc. $CUE

Northwestern Mutual Wealth Management Co. decreased its stake in shares of Cue Biopharma, Inc. (NASDAQ:CUE) by 96.7% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,632 shares of the company’s stock after selling 76,868 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Cue Biopharma were worth $83,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of CUE. ADAR1 Capital Management LLC purchased a new stake in Cue Biopharma in the second quarter worth about $1,742,000. BlackRock Inc. bought a new position in shares of Cue Biopharma in the 2nd quarter worth approximately $1,824,000. Texas Capital Bank Wealth Management Services Inc bought a new stake in shares of Cue Biopharma during the second quarter valued at approximately $722,000. Seven Fleet Capital Management LP bought a new stake in shares of Cue Biopharma during the second quarter valued at approximately $338,000. Finally, Boothbay Fund Management LLC purchased a new stake in Cue Biopharma in the third quarter worth $439,000. Hedge funds and other institutional investors own 35.04% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on CUE. Wall Street Zen lowered Cue Biopharma from a “hold” rating to a “sell” rating in a research report on Sunday, August 23rd. Weiss Ratings downgraded shares of Cue Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 27th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

Cue Biopharma Stock Performance

CUE stock opened at $30.00 on Wednesday. The firm has a 50 day moving average price of $29.23 and a 200-day moving average price of $114.02. Cue Biopharma, Inc. has a 52-week low of $4.97 and a 52-week high of $45.50. The firm has a market capitalization of $217.80 million, a price-to-earnings ratio of -1.11 and a beta of 2.45.

Cue Biopharma (NASDAQ:CUE) last posted its quarterly earnings results on Friday, August 14th. The company reported ($24.14) earnings per share for the quarter, missing the consensus estimate of ($1.69) by ($22.45). The company had revenue of $7.88 million during the quarter, compared to analysts’ expectations of $3.00 million. Cue Biopharma had a negative return on equity of 620.06% and a negative net margin of 435.83%.

Insider Transactions at Cue Biopharma

In other news, CEO Shao-Lee Lin sold 18,258 shares of Cue Biopharma stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $28.62, for a total value of $522,543.96. Following the completion of the transaction, the chief executive officer owned 705,995 shares of the company’s stock, valued at $20,205,576.90. The trade was a 2.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, VP Michael Vincent Meluzio sold 5,628 shares of the company’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $30.09, for a total transaction of $169,346.52. Following the completion of the transaction, the vice president owned 48,961 shares in the company, valued at approximately $1,473,236.49. The trade was a 10.31% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 72,715 shares of company stock valued at $2,041,555. Insiders own 14.56% of the company’s stock.

About Cue Biopharma

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.